In preclinical models, anakinra was effective in diminishing IL-1β production and mitigating inflammation in patients with cystic fibrosis and chronic granulomatous disease, which have an increased risk for fungal infections and the activation of inflammasomes [108]. This evidence concerns the gene IL1B and fungal infectious disease.